US · Healthcare · Medical Care Facilities
EPS came in at 0.40 against a street estimate of 0.31 — a beat of 29.0%.
Analysts rate Astrana Health Inc a strong buy (9 buy, 3 hold, 0 sell out of 12) with an average price target of $51.50.
CONFIDENT Astrana beat Q2 expectations with 49% revenue growth and record EPS of $0.80. Raised full-year EBITDA guidance while reinvesting outperformance into growth. Prospect integration tracking well; net leverage improved to 2.26x ahead of schedule. Q2 2026 Texas delegated full-risk partnership is 2 full quarters into operation, performing in line with expectations, with net new professional risk members added. Hawaii represents opportunity for scaled provider entity. California remains core market but increasingly rebalanced toward full-risk arrangements. Analysts pressed on commercial trend drivers, Medicaid transitions economics, and Q4 EBITDA range width. Management disclosed commercial concentration in outpatient (manageable), confirmed tens of thousands Medi-Cal conversions without separate earnings sizing, and clarified Q4 range as artifact of annual guidance width rather than …
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 12.43% |
| Vanguard Portfolio Management, LLC | 4.59% |
| Vanguard Capital Management, LLC | 3.45% |
| State Street Corp | 3.33% |
| 325 Capital LLC | 3.25% |
| Dimensional Fund Advisors, Inc. | 2.96% |
| Wellington Management Company LLP | 2.61% |
| Geode Capital Management, LLC | 2.09% |
| Document | Date |
|---|---|
| Reg FD disclosure · Q3 2026 ASTRANA HEALTH, INC. — FORM 8-K SUMMARY OTHER NOTABLE POINTS • Document Type & Date: Form 8-K current report filed September 15, 2026 by Astrana Hea | 2026-09-15 |
| Quarterly report · Q2 2026 ASTRANA HEALTH, INC. – 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Capitation and other revenue, net: $1,937,620 thousand ($1.938 billion) for six mon | 2026-08-10 |
| Results announced · Q3 2026 ASTRANA HEALTH, INC. – Q2 2026 EARNINGS SUMMARY --- HEADLINE NUMBERS • Q2 2026 Revenue: $972.5 million, up 49% year-over-year (Q2 2025: $654.8 mill | 2026-08-06 |
| Reg FD disclosure · Q3 2026 ASTRANA HEALTH, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Company issued press release on July 13, 2026 regarding accountable care organizations (A | 2026-07-13 |
| Board / officer change · Q2 2026 ASTRANA HEALTH, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • No material financial numbers disclosed in this filing • Company: Astrana Health, Inc. (T | 2026-07-01 |
| Board / officer change · Q2 2026 ASTRANA HEALTH, INC. – FORM 8-K SUMMARY Report Date: June 10, 2026 --- BUSINESS & SEGMENT HIGHLIGHTS • Astrana Health is a publicly traded company | 2026-06-10 |
| Quarterly report · Q1 2026 ASTRANA HEALTH, INC. – FORM 10-Q SUMMARY Quarter Ended March 31, 2026 --- HEADLINE NUMBERS • Total Revenue: $965.1 million (Q1 2026) vs. $620.4 mil | 2026-05-08 |
| Proxy statement · Q2 2026 ASTRANA HEALTH, INC. — 2026 ANNUAL MEETING PROXY SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect nine directors to the Board (nominees: | 2026-04-17 |
Readable in the app.
| Announcement | Date |
|---|---|
| Completed acquisition of health plan and hospital assets from Prospect Medical Astrana Health, Inc. completed its acquisition of Prospect Health Plan, Inc., Alta Newport Hospital (Foothill Regional Medical Center), and related assets from Prospect Medical Holdings in 2 | 2026-03-30 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Astrana Health Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.